We headed into the
City first thing this morning for my MRI at the Memorial Sloan Kettering Cancer
Center building on East 55th Street, followed by my appointment with
Dr. Lisa DeAngelis at the Outpatient Pavilion on East 53rd Street.
My last MRI had been on February 6th of 2018, nearly twenty-one
months ago.
The news is good – I
am still in the clear! So, after we chatted for a few minutes, it was not
entirely surprising when Dr. DeAngelis said that there is no need for me to
schedule any further routine follow-up appointments with her.
I first saw Dr. DeAngelis
in the spring of 2012. The primary CNS lymphoma had been diagnosed at Mount
Sinai Hospital, but because it is a relatively rare tumor, the doctors and
staff there did not have much experience treating it, and much to their credit,
those doctors encouraged us to head over to Dr. DeAngelis at MSKCC. The rest,
as they say, is history.
As I was writing
this, I entered “Lisa DeAngelis” into Google and lo and behold came across
something I had somehow completely missed earlier last month:
Neuro-Oncologist Lisa M. DeAngelis Has Been Named
Physician-in-Chief and Chief Medical Officer of Memorial Sloan Kettering Cancer
Center
Lisa
M. DeAngelis Has Been Named Physician-in-Chief and Chief Medical Officer of MSK
Tuesday, September 10, 2019
After an extensive nationwide search, Memorial Sloan
Kettering Cancer Center (MSK) announced today that Lisa M. DeAngelis has been named
Physician-in-Chief and Chief Medical Officer. A leading expert in brain cancer,
Dr. DeAngelis previously served as Chair of the Department
of Neurology and was co-founder of MSK’s Brain Tumor Center during her
30-plus-year tenure at the institution.
“Lisa is an internationally renowned physician,
collaborative colleague, and fierce advocate for both patients and faculty,”
said Craig B. Thompson, MSK President and CEO. “Her
expertise and unique understanding of MSK’s mission make her the ideal person
to lead MSK’s clinical enterprise into the future.”
As Physician-in-Chief, Dr. DeAngelis will direct the entire
clinical care enterprise and continuum of care at MSK, leading a staff of
cancer experts that includes more than 1,200 hospital attendings and almost
4,000 registered nurses. She will be responsible for the management of all
patient care services across the MSK system, including a 500-bed inpatient
hospital, 13 outpatient facilities in New York City, and seven regional care
sites throughout New York and New Jersey. She will also focus on clinical
strategic planning and will oversee MSK’s robust clinical and translational
research programs.
“Over the course of her career, Lisa has been a leader of
strength and integrity and is widely recognized for her vast knowledge of MSK,
her extensive experience in treating cancer, and her extraordinary skill as a
physician. She is also a gifted communicator, and there is no one better suited
for this trailblazing role,” said Scott M. Stuart, Chairman of the Boards of
Overseers and Managers of MSK.
Dr. DeAngelis joined MSK as a neuro-oncology fellow in 1985,
working with Jerome Posner, who was MSK’s founding Chair of Neurology. She
became a critical member of MSK’s leadership team in 1997, when she was
appointed Chair of the Department of Neurology, a position she held until
assuming the Acting Physician-in-Chief role in September 2018. She co-founded
MSK’s Brain Tumor Center, where experts from across MSK work to bring new
discoveries from the lab to patients as quickly as possible. Her research has
focused on primary brain tumors and the neurological complications of cancer
and its treatment, such as cognitive impairment and strokes. She helped develop
the current regimen to treat primary central nervous system lymphoma and has led
numerous national clinical trials that investigate new brain tumor therapies.
Dr. DeAngelis is an elected member of the National
Academy of Medicine and a fellow of the American
Academy of Neurology and the American Neurological Association.
She also served previously on the board of directors for the Society
for Neuro-Oncology.
MSK
is one of 50 institutions in the United States that has been designated a Comprehensive Cancer Center by the National Cancer
Institute, affirming our leadership in research, patient care, and
education. MSK is an American Nurses Credentialing
Center Magnet®–designated institution, based on nursing excellence. In
2018, more than 24,000 patients were admitted to Memorial Hospital, and more
than 173,000 patients were seen at our Manhattan and regional facilities.
From where I sit,
MSKCC would have been hard pressed to make a better selection!
Love,
Rebecca
No comments:
Post a Comment